April 2016

Predictive biomarkers are revamping drug development and breathing new life into old and failed drugs. But this re-thinking of what works, in who, and why raises questions about cost and accessibility. Precision may be pricy.

Michael D. Dalzell
Michael D. Dalzell

When Alexander Graham Bell phoned it in, so to speak, who could have predicted that it would eventually lead to IBM’s Watson Health tackling medication adherence with state-of-the-art analytics?

Jan Greene

Information overload from a flood of new diagnostics forces insurers to ramp up prior authorization and utilization review.

Joseph Burns

Manufacturers are starting to offer significant rebates in exchange for preferred status on an insurer’s formulary.

Thomas Reinke

California and other states have put monthly caps on out-of-pocket medication expenses. But the caps might shift some costs over to premiums.

Joseph Burns
The Value of Drugs: It Is Not About the Money!
Interview by Peter Wehrwein
Ana D. Vega, BS
Paul P. Meola, BS
Julio Ramon Barcelo Jr.
Heidi M. Perez Ruiz, BS
Stephanie A. Oh, PharmD

Legislation & Regulation
It seems like Godot may arrive sooner. Seven years after the biosimilar law was enacted, stakeholders are losing patience with the FDA.
Richard Mark Kirkner
Legal Front

A Harvard Law School group is among those that have taken action.

Ed Silverman

Managed care organizations need to work on several fronts if they are to improve patient adherence. Limiting out-of-pocket costs is one place to start.

Richard G. Stefanacci, DO
Tomorrow’s Medicine

Sarepta’s eteplirsen functions like an RNA patch so functioning dystrophin gets made. Other drugs like it may be used to treat Ebola and other viral infections.

Thomas Morrow, MD
Biologics in Development
Katherine T. Adams
Cancer Watch
Organized oncology isn’t ready to give up on ASP+6 payment for Medicare Part B drugs. But experimentation with value-based pricing has some supporters.
Peter Wehrwein